Pharma industry groups backed proposed changes to the HHS 340B rebate pilot, according to reporting tied to Health Resources and Services Administration (HRSA) updates. The revised pilot would let some drug manufacturers deny rebates for a limited subset of drugs, shifting how covered entities receive 340B pricing for participating products. The 340B program—designed to expand access to medications for safety-net providers—has been a recurring flashpoint for pricing and reimbursement. This latest revision matters because it affects downstream economics for manufacturers, payers, and dispensing providers, even when overall affordability goals remain intact. For manufacturers, the change may reduce exposure for specific categories of drugs; for hospitals and pharmacies, it can alter which products generate 340B-linked rebates, potentially changing purchasing and formulary behavior.